Peter Marco, MD
Pulmonary Disease · Panama City, FLNPI 1013975119
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $717 and has fallen 80.8% since, to $137 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 75 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$223
- Abiomed$137
- Electromed, Inc.$130
- Actelion Pharmaceuticals US, Inc.$130
- Insmed, Inc.$110
- AbbVie$109
- plus $360 from 11 others
What the payments were for
- Food & beverage$1,200100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $223 |
| Abiomed | 1 | $137 |
| Electromed, Inc. | 13 | $130 |
| Actelion Pharmaceuticals US, Inc. | 13 | $130 |
| Insmed, Inc. | 7 | $110 |
| AbbVie | 5 | $109 |
| Philips North America LLC | 6 | $96 |
| Inspire Medical Systems, Inc. | 3 | $69 |
| Sunovion Pharmaceuticals Inc. | 4 | $39 |
| Nestle Healthcare Nutrition Inc. | 1 | $32 |
| Gilead | 2 | $27 |
| United Therapeutics Corporation | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Merck | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,200 in reported general payments places this provider in the 35th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Panama City
- William McKenziePanama City$361K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.